Market Overview

After Q3, Patience Is A Virtue For FireEye Investors

Share:
After Q3, Patience Is A Virtue For FireEye Investors

Despite a more than 10 percent sell-off in FireEye Inc (NASDAQ: FEYE)'s stock Thursday morning, Morgan Stanley analysts think the company's earnings report marks an "early turnaround" in its business. The firm's Melissa Franchi maintains an Overweight rating on FireEye's stock with an unchanged $19 price target.

FireEye's third-quarter earnings report showed a stabilization across many areas, an important step in the company's turnaround plans, Franchi said in a Thursday note. (See Franchi's track record here.)

Billings declined just 6 percent on a year-over-year basis, marking an improvement from a 12 percent decline last quarter, according to Morgan Stanley.

The company also saw improvements in new product adoption, including approximately 28 new paying Helix customers, up from 10 new additions in the prior quarters, Franchi said. It's stil early in the Helix life cycle and management continues to tweak the product, she said. 

FireEye's management team is showing excellent cost discipline, as operating expenditures were lower by 9 percent from a year ago, and operating margins rose 1,200 basis points, the analyst said. Looking forward to fiscal 2018, FireEye should see 13 percent billings growth (versus a 9 percent decline in fiscal 2018), which implies the company is "well-positioned" for the coming year and beyond, Franchi said. 

"Patience is a virtue" as FireEye's "product strategy is still gelling but easy comps, ramping renewals and low [expectations] on new product adoption keeps FEYE attractive thru CY18," Franchi said. 

Oppenheimer: 'Healthy' Results

FireEye's Q3 results were "decent," and the company has reaffirmed its commitment to reducing expenses, Oppenheimer's Shaul Eyal said in a Thursday note. 

Despite this, the company's fourth quarter billings guidance implies a 0.5 percent year-over-year decline due to shorter-than-expected contract lengths, Eyal said. 

As a whole, FireEye is "executing well" with a renewed product portfolio, the analyst said. Certain product lines within the unattached subscription product line, including Cloud HX, Helix and iSIGHT, realized "robust" performance during the quarter, according to Oppenheimer. Of particular note, the company realized a record-breaking quarter for the endpoint product HX, and management added 57 new Helix customers for a total of 71.

While positive execution in certain product segments is a positive, predictability for the company as a whole "remains a slight challenge" moving forward, Eyal said. 

Eyal maintains an Outperform rating on FireEye's stock with an unchanged $22 price target.

Related Links:

FireEye's Turnaround Is Clearly Underway After Q2 Beat

The Bull Case For FireEye Presents Potential For 100% Upside From Here

Latest Ratings for FEYE

DateFirmActionFromTo
Nov 2019Initiates Coverage OnNeutral
Oct 2019Initiates Coverage OnHold
Aug 2019Initiates Coverage OnBuy

View More Analyst Ratings for FEYE
View the Latest Analyst Ratings

Posted-In: Cybersecurity Helix Melissa Franchi Morgan StanleyAnalyst Color Reiteration Analyst Ratings Tech Best of Benzinga

 

Related Articles (FEYE)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MJP MorganMaintains13.0
IPARDA DavidsonMaintains76.0
BSBRUBSUpgrades
TGTMorgan StanleyMaintains130.0
VCMorgan StanleyMaintains52.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Antitrust Suit Could Block AT&T's Purchase Of Time Warner

Zimmer Biomet's Q3 Miss-And-Cut Casts Doubt On The Bull Thesis